1. Home
  2. NCNA vs ADVB Comparison

NCNA vs ADVB Comparison

Compare NCNA & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$1.90

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

ADVB

Advanced Biomed Inc.

HOLD

Current Price

$5.58

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNA
ADVB
Founded
1997
2014
Country
United Kingdom
United States
Employees
N/A
31
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
10.1M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
NCNA
ADVB
Price
$1.90
$5.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.0K
79.5K
Earning Date
06-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$1.26
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.19
52 Week High
$10.00
$7.70

Technical Indicators

Market Signals
Indicator
NCNA
ADVB
Relative Strength Index (RSI) 43.97 45.45
Support Level $1.33 $0.33
Resistance Level $2.27 $5.95
Average True Range (ATR) 0.15 0.95
MACD -0.02 -0.04
Stochastic Oscillator 26.09 7.99

Price Performance

Historical Comparison
NCNA
ADVB

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

About ADVB Advanced Biomed Inc.

Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

Share on Social Networks: